Rapport Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2022-01-01
- Employees
- 58
- Market Cap
- -
- Website
- http://www.rapportrx.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (33.3%)Phase 1
1 (33.3%)Phase 2
1 (33.3%)Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
Not Applicable
Not yet recruiting
- Conditions
- Bipolar 1 Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Rapport Therapeutics Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT07046494
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Rapport Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06377930
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Consultants in Epilepsy and Neurology, PLLC, Boise, Idaho, United States
🇺🇸IU Health Neuroscience Center, Goodman Hall, Indianapolis, Indiana, United States
News
No news found